Investors should consider exploring various cutting-edge healthcare companies, and Catheter Precision, Inc. (NYSE American: VTAK) stands out as a notable player. Specializing in non-invasive mapping for ventricular arrhythmias, the company gained attention on January 17, 2023. It made headlines by featuring its product, the VIVO System, in a case study highlighted in the latest issue of the EP Lab Digest.
It is important to highlight that EP Lab Digest serves as a monthly educational publication with a specific focus on electrophysiology, providing content through both print and online platforms. David Jenkins, the Chief Executive Officer of Catheter Precision, Inc., shared insights on this recent development. He emphasized that the inclusion of a case study in the publication signaled the publication committee’s recognition of the valuable work conducted by physicians at New York University, considering it beneficial for fellow electrophysiologists. Jenkins further pointed out the uniqueness of the case study, highlighting its initiation by physicians.
An essential aspect to consider regarding Catheter Precision’s procedures is their non-invasive nature, ensuring swift delivery of results. The VIVO System streamlines catheter ablation, producing outcomes comparable to those achieved through conventional methods. Presently, various methods can be employed for this purpose; however, the company’s procedures stand out for delivering equivalent effectiveness at a reduced cost and an accelerated pace. Extensive research has been conducted to assess the efficiency offered by these non-invasive processes.
On Friday, January 19, 2024, VTAK registered an 8.14% increase accompanied by trading activity 5x the average volume. Significantly, the stock exceeded its 20-day moving average (DMA), indicating improved short-term potential. Furthermore, there is anticipation of the stock surpassing its 50 DMA, potentially triggering an immediate breakout into an upward trend.